Warp Sciences raises $215 million to challenge overseas chemistry outsourcing labs

By SKYSEVEN Chemical Technical Team · 2026-11-04

Share:

A start-up led by the former OpenAI executive Kevin Weil says it has raised $215 million to challenge overseas contractors that make experimental drug compounds for pharmaceutical and biotechnology companies.

The company, Warp Sciences, announced the financing Oct. 22; Lightspeed Venture Partners led the round. Warp plans to combine synthetic chemists, artificial intelligence, and robots in a US medical contract research organization (CRO). Much of the labor-intensive work of making compounds to drug discovery has been outsourced to reduce-cost providers such as the Chinese firm WuXi AppTec.

Previous

Syensqo ends fluorosurfactants production in Italy

Next

Sodium Bicarbonate Prices Saw Overall Consolidation in October

Quick inquiry

Create

Inquiry Sent

We will contact you soon